Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.
Stocks · News reference
FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades
FTC and 7 states seek contempt against Martin Shkreli, alleging he violated his lifetime pharma ban by trading biotech stocks and influencing markets.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Travere Therapeutics Says USPTO Allowed Patent For FILSPARI In FSGS, Expected To Provide Coverage Into October 2037
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.